Document is current
Any future updates will be listed below
-
Authors
Bonsor, Daniel A.
Alexander, Patrick
Snead, Kelly
Hartig, Nicole
Drew, Matthew
Messing, Simon
Finci, Lorenzo I.
Nissley, Dwight V. https://orcid.org/0000-0001-7523-116X
McCormick, Frank https://orcid.org/0000-0002-6619-7120
Esposito, Dominic https://orcid.org/0000-0002-9987-1687
Rodriguez-Viciana, Pablo
Stephen, Andrew G. https://orcid.org/0000-0002-8259-621X
Simanshu, Dhirendra K. https://orcid.org/0000-0002-9717-4618
- License Information
-
More Information
Article History
Received: 17 February 2022
Accepted: 12 August 2022
First Online: 29 September 2022
Competing interests
: F.M. is a consultant for Amgen, Daiichi, Frontiers Med, Exuma Biotech, Ideaya Biosciences, Kura Oncology, Leidos Biomedical Research, PellePharm, Pfizer, P.M.V. Pharma, and Quanta Therapeutics. F.M. is a consultant and co-founder for (with ownership interest including stock options) BridgeBio, Olema Pharmaceuticals, and Quartz. F.M. has received research grants from Daiichi Sankyo and Gilead Sciences and has a current grant from Boehringer-Ingelheim. The remaining authors declare no competing interests.
